Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Mark Andrew Borden · UNIVERSITY OF COLORADO · 2021 · $352,275 — The development of new pharmaceuticals for the treatment of brain cancer and neurological disease has outpaced our ability to deliver them safely, largely due to the blood-brain barrier (BBB). Bypassing the BBB to access the brain parenchyma is often highly invasive, involving surgery to remove part…
Elizabeth A Nance · UNIVERSITY OF WASHINGTON · 2021 · $222,108 — PROJECT SUMMARY/ABSTRACT Perinatal asphyxia (PA), where newborn infants suffer from a lack of oxygen and blood flow to the brain, is a leading cause of morbidity and mortality around the time of birth. PA in term infants, and the resulting neurodevelopmental sequelae such as intellectual disability,…
Sashwati Roy · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $393,750 — ABSTRACT Persistent unresolved inflammation impairs diabetic wound healing. The function and fate of wound monocyte/macrophages (mϕ) hold the key to the outcome of wound inflammation. This proposal builds on observations originating from live functional wound macrophages (wmϕ) and wound fluid derive…
ZHENG-RONG LU · CASE WESTERN RESERVE UNIVERSITY · 2021 · $23,693 — 3.8.1 Research, mentoring and career development 1). Research Plan 1.1). Abstract of the parent grant The goal of this project is to develop smart dual-targeted lipid ECO/siRNA self-assembly nanoparticles to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat metastatic and …
Andre Elias Nel · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $553,064 — The use of nano-enabled chemotherapy to trigger an immune response to pancreatic ductal adenocarcinoma (PDAC) introduces a novel approach for overcoming robust barriers to immunotherapy, including poor immunogenicity, low neoantigen burden, stromal interference (“T-cell exclusion”), overexpression o…
Joe L Hsu · STANFORD UNIVERSITY · 2021 · $592,966 — PROJECT SUMMARY/ ABSTRACT This application focuses on the contribution of transplant hemorrhage-induced iron overload in the dysregulation of pulmonary macrophages (mɸs) and the promotion of invasive aspergillosis. Aspergillus fumigatus (Af) is a ubiquitous mold that releases airborne spores (conidi…
Takahisa Kanekiyo · NORTH DAKOTA STATE UNIVERSITY · 2021 · $1,437,570 — SUMMARY/ABSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that has emerged as the most prevalent form of late-life dementia in humans. The accumulation, aggregation, and deposition of amyloid-β (Aβ) in the brain are central events in AD pathogenesis. Despite intense effor…
Amaia Lujambio · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $620,173 — Chronic liver disease and its common sequela cirrhosis, are growing public health concerns, and major risk factors for the development of hepatocellular cancer (HCC). HCC incidence and mortality is growing in the USA. Optimal medical therapies for HCC are lacking. FDA approved agents are modestly ef…
Sean German · ELECTRONIC BIOSCIENCES, INC. · 2021 · $400,000 — Project Summary Electronic BioSciences (EBS) proposes, in collaboration with Distinguished Professor Henry White at the University of Utah, to develop a nanopore-based extracellular vesicle (EV) characterization system capable of high-resolution, single-vesicle, solution-based characterization, sort…
DANIEL J GIBSON · INTEGUMED, LLC · 2021 · $299,749 — ABSTRACT Chronic wounds affect over 2.5 million patients in the US alone, lasting on average 12-13 months and recurring in 60-70% of patients. These occur primarily in lower extremities and vascular disease, diabetes, nephropathy, and metabolic dysfunction are prevalent co-morbidities. These wounds …
Yizhou Dong · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $653,455 — Immunotherapy treatments such as checkpoint blockade and chimeric antigen receptor T cell therapy have demonstrated the power of the immune system to eradicate metastatic cancer, but the efficacy of immunotherapies in solid tumors remains confined to a minority of patients. A series of interlinked e…
ZHENG-RONG LU · CASE WESTERN RESERVE UNIVERSITY · 2021 · $357,780 — The goal of this project is to develop smart dual-targeted lipid ECO/siRNA self-assembly nanoparticles to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat metastatic and drug-resistant triple negative breast cancer (TNBC). Metastasis and drug resistance are the main causes…
MICHAEL P CZECH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2021 · $582,900 — Abstract The overarching long term goal of our laboratory is to understand and exploit how adipose tissues exert powerful control over whole body glucose tolerance and insulin sensitivity. Small amounts of mouse brown (BAT) or human “Beige” adipocytes transplanted into recipient mice can improve glu…
TIMOTHY M GRIFFIN · OKLAHOMA CITY VA MEDICAL CENTER · 2021 — Osteoarthritis (OA) disproportionately affects veterans, resulting in more pain and functional limitations compared to the general population. No disease-modifying treatments exist for OA, and current pain medications (e.g., opioids and NSAIDs) have limited long-term efficacy and adverse side effect…
Rajagopal Ramesh · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2021 · $350,939 — Effective control of lung cancer continues to remain a clinical challenge resulting in poor five-year survival rate. Currently available therapies while showing promise have had limitations. Therefore, continued efforts for developing new therapeutic agents and systemic treatment modalities are warr…
HUGO Ramon ROSEN · UNIVERSITY OF SOUTHERN CALIFORNIA · 2021 · $371,250 — PROJECT SUMMARY /ABSTRACT Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, affecting at least a quarter of the world’s population, and therefore highly relevant to the NIH mission. From steatosis to fibrosis, hepatic inflammation drives disease progression…
Joshua A Kritzer · TUFTS UNIVERSITY MEDFORD · 2021 · $285,398 — Cell Penetration Profiling for Biotherapeutics Biotechnology promises the ability to control biology and disease with laser-like precision. Hundreds of peptides, proteins and nucleic acids are being developed as diagnostics and therapies, but nearly all of these have poor cell penetration and unpred…
michele k evans · NATIONAL INSTITUTE ON AGING · 2021 · $695,374 — We characterized EV attributes across selected age groups of participants from the population based, longitudinal study, Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) in LEPS. We analyzed circulating plasma EVs from the HANDLS study using both a cross-sectional and longit…
S. Munir ALAM · DUKE UNIVERSITY · 2021 · $325,000 — Induction of broadly neutralizing antibodies (bnAbs) is a critical unmet goal of HIV vaccine development. BnAb DH511 is of high interest as a vaccine lead due to its very high breadth and the high in vivo protective potency of MPER bNAbs. Key challenges for inducing DH511-like bnAbs are: (a) the low…
TIMOTHY J. WILKIN · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $1,013,863 — Clinical Trials Program Project Summary/Abstract The overall goal of the proposal is to advance prevention interventions for HPV-associated cancers occurring among men and women living with HIV in Latin America and the Caribbean (LAC). We are focusing on prevention of two HPV-associated cancers, or…